Your browser doesn't support javascript.
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
Wang, Hui; Zhang, Yuntao; Huang, Baoying; Deng, Wei; Quan, Yaru; Wang, Wenling; Xu, Wenbo; Zhao, Yuxiu; Li, Na; Zhang, Jin; Liang, Hongyang; Bao, Linlin; Xu, Yanfeng; Ding, Ling; Zhou, Weimin; Gao, Hong; Liu, Jiangning; Niu, Peihua; Zhao, Li; Zhen, Wei; Fu, Hui; Yu, Shouzhi; Zhang, Zhengli; Xu, Guangxue; Li, Changgui; Lou, Zhiyong; Xu, Miao; Qin, Chuan; Wu, Guizhen; Gao, George Fu; Tan, Wenjie; Yang, Xiaoming.
  • Wang H; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Zhang Y; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Huang B; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Deng W; National Animal Models for Human Diseases Resources Center, NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Me
  • Quan Y; National Institute for Food and Drug Control, Beijing, China.
  • Wang W; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Xu W; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Zhao Y; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Li N; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Zhang J; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Liang H; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Bao L; National Animal Models for Human Diseases Resources Center, NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Me
  • Xu Y; National Animal Models for Human Diseases Resources Center, NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Me
  • Ding L; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Zhou W; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Gao H; National Animal Models for Human Diseases Resources Center, NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Me
  • Liu J; National Animal Models for Human Diseases Resources Center, NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Me
  • Niu P; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Zhao L; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Zhen W; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Fu H; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Yu S; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Zhang Z; Beijing Institute of Biological Products Company Limited, Beijing, China.
  • Xu G; MOE Key Laboratory of Protein Science & Collaborative Innovation Center of Biotherapy, School of Medicine, Tsinghua University, Beijing, China.
  • Li C; National Institute for Food and Drug Control, Beijing, China. Electronic address: changguili@aliyun.com.
  • Lou Z; MOE Key Laboratory of Protein Science & Collaborative Innovation Center of Biotherapy, School of Medicine, Tsinghua University, Beijing, China. Electronic address: louzy@mail.tsinghua.edu.cn.
  • Xu M; National Institute for Food and Drug Control, Beijing, China. Electronic address: xumiaobj@126.com.
  • Qin C; National Animal Models for Human Diseases Resources Center, NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Me
  • Wu G; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. Electronic address: wugz@ivdc.chinacdc.cn.
  • Gao GF; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. Electronic address: gaofu@chinacdc.cn.
  • Tan W; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. Electronic address: tanwj@ivdc.chinacdc.cn.
  • Yang X; Beijing Institute of Biological Products Company Limited, Beijing, China. Electronic address: yangxiaoming@sinopharm.com.
Cell ; 182(3): 713-721.e9, 2020 08 06.
Article in English | MEDLINE | ID: covidwho-549043
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 µg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Vaccines, Inactivated / Coronavirus Infections / Drug Evaluation, Preclinical / Pandemics / Betacoronavirus Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Traditional medicine / Vaccines Limits: Animals Language: English Journal: Cell Year: 2020 Document Type: Article Affiliation country: J.cell.2020.06.008

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Vaccines, Inactivated / Coronavirus Infections / Drug Evaluation, Preclinical / Pandemics / Betacoronavirus Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Traditional medicine / Vaccines Limits: Animals Language: English Journal: Cell Year: 2020 Document Type: Article Affiliation country: J.cell.2020.06.008